Clinical trial
The Combination of Oral All-trans Retinoic Acid and High-dose Dexamethasone vs High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Trial
NCT04217148 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Combination of Oral All-trans Retinoic Acid and High-dose Dexamethasone vs High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Trial
- Lead sponsor
- Peking University People's Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 1, 2020
- Completion date
- June 30, 2020
- Enrollment
- 132 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
immune thrombocytopenia